COVID-19 Vaccination Uptake Among Individuals With Immune-mediated Inflammatory Diseases in Ontario, Canada, Between December 2020 and October 2021: A Population-based Analysis

Jessica Widdifield1, Lihi Eder2, Simon Chen3, Jeffrey C. Kwong4, Carol Hitchon4, Diane Lacaille6, J. Antonio Aviña-Zubieta6, Lawrence W. Svenson7, and Sasha Bernatsky8

ABSTRACT. Objective. We assessed coronavirus disease 2019 (COVID-19) vaccine uptake among individuals with immune-mediated inflammatory diseases (IMIDs) and the Ontario general population.

Methods. We studied all residents aged ≥ 16 years who were alive and enrolled in the Ontario Health Insurance Plan as of December 14, 2020, when vaccination commenced (n = 12,435,914). Individuals with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis (PsO), and inflammatory bowel disease (IBD) were identified using established disease-specific case definitions applied to health administrative data. Vaccination status was extracted from the provincial COVaxON registry. Weekly cumulative proportions of first and second doses up until October 3, 2021, were expressed as the vaccinated percentage of each disease group, compared to the general Ontario population, and stratified by age.

Results. By October 3, 2021, the cumulative percentage with at least 1 dose was 82.1% for the general population, 88.9% for those with RA, 87.4% for AS, 90.6% for PsA, 87.3% for PsO, and 87.0% for IBD. There was also a higher total cumulative percentage with 2 doses among IMIDs (83.8–88.2%) vs the general population (77.9%). The difference was also evident when stratifying by age. Individuals with IMIDs in the youngest age group initially had earlier uptake than the general population but remain the lowest age group with 2 doses (70.6% in the general population vs. 73.7–79.2% across IMID groups).

Conclusion. While implementation of COVID-19 vaccination programs has differed globally, these Canadian estimates are the first to reassuringly show higher COVID-19 vaccine uptake among individuals with IMIDs.

Key Indexing Terms: COVID-19, inflammatory bowel disease, psoriasis, rheumatic diseases, vaccination

This project was supported by funding from the Public Health Agency of Canada (PHAC), through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force. The views expressed herein do not necessarily represent the views of the PHAC. The study was supported by ICES (formerly known as the Institute for Clinical Evaluative Sciences), which is funded by the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care. Parts of this material are based on data and information compiled and provided by the MOH and the Canadian Institute for Health Information. The opinions, results, and conclusions reported in this paper are those of the authors and are independent of the data sources; no endorsement is intended or should be inferred. JW receives support from the Arthritis Society Stars Career Development Award (STAR-19-0610). LE is Canada Research Chair (Tier 2) in Equity in Care of Rheumatic Disorders. DL is the Mary Pack Chair in Rheumatology Research from the University of British Columbia and The Arthritis Society. JAAZ is the BC Lupus Society Research Scholar and the Walter and Marilyn Booth Research Scholar. SB is a James McGill Professor of Medicine.

1J. Widdifield, PhD, Assistant Professor, Institute of Health Policy, Management & Evaluation, University of Toronto, Sunnybrook Research Institute, Holland Bone & Joint Program, Toronto, and ICES, Toronto, Ontario; 2L. Eder, MD, PhD, Associate Professor, University of Toronto, and Women’s College Research Institute, Women’s College Hospital, Toronto, Ontario; 3S. Chen, MPH, ICES, Toronto, Ontario; 4J.C. Kwong, MD, MSc, FRCPC, Professor, Department of Family and Community Medicine, Faculty of Medicine, and Dalla Lana School of Public Health, University of Toronto, ICES, Toronto, and Public Health Ontario, Toronto, Ontario; 5C. Hitchon, MD, MSc, Associate Professor, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba; 6D. Lacaille, MD, MHS, FRCPC, Professor, J.A. Aviña-Zubieta, MD, PhD, FRCPC, Associate Professor, Division of Rheumatology, Department of Medicine, University of British Columbia, and Arthritis Research Canada, Vancouver, British Columbia; 7L.W. Svenson, PhD, Analytics and Performance Reporting Branch, Alberta Health, Edmonton, Division of Preventive Medicine, University of Alberta, Edmonton, School of Public Health, University of Alberta, Edmonton, and Department of Community Health Sciences, University of Calgary, Calgary, Alberta; 8S. Bernatsky, MD, FRCPC, PhD, Professor, Divisions of Rheumatology and Clinical Epidemiology, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada.

The authors declare no conflicts of interest relevant to this article.

Address correspondence to Dr. J. Widdifield, Sunnybrook Research Institute, MG 352 - 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada. Email: jessica.widdifield@utoronto.ca.

Accepted for publication December 20, 2021.

© 2022 The Journal of Rheumatology. This is an Open Access article, which permits use, distribution, and reproduction, without modification, provided the original article is correctly cited and is not used for commercial purposes.
Immune-mediated inflammatory diseases (IMIDs) comprise a clinically diverse group of conditions characterized by altered immune regulation causing chronic inflammation in targeted organs or systems. Immune dysregulation, immunosuppressant treatment, and other risk factors including multimorbidity make individuals with IMIDs vulnerable to severe coronavirus disease 2019 (COVID-19) outcomes.\textsuperscript{1,2} Despite the initial lack of safety and efficacy data on COVID-19 vaccines within this patient population (as patients with IMIDs were excluded from the first clinical trials), most professional organizations and regulatory bodies recommended that patients with IMIDs be prioritized for vaccination when vaccination programs commenced.\textsuperscript{3-6}

Despite a slow start in early 2021, Canada has had mostly successful provincial COVID-19 vaccination programs involving 3 vaccines: BNT162b2/Pfizer-BioNTech, mRNA-1273/Moderna, and ChAdOx1 nCoV-19/AstraZeneca/COVISHIELD. By summer 2021, there was enough vaccine supply in Canada to meet the needs of the entire population. As global vaccination campaigns are still underway, including efforts to commence third doses, it is unknown whether vaccine uptake (with initial 2-dose regimens) among individuals with IMIDs is comparable to the general population or whether delays in uptake have occurred. Vaccine hesitancy may be amplified among IMID populations, owing to potential vaccine efficacy and potential safety concerns that patients may have (eg, concerns over local or systemic reactogenicity, disease worsening or flare,\textsuperscript{7} negative experiences from prior vaccines,\textsuperscript{8} and the changing guidance on immunosuppressive treatment adjustments\textsuperscript{9}). Therefore, we compared the COVID-19 vaccine uptake among individuals with IMIDs and the general population in Ontario (Canada’s most populous province).

METHODS

Setting. Ontario is one of 10 provinces of Canada, representing 40\% of the country’s population. Ontario is also Canada’s most ethnically diverse province, composed of individuals with approximately 250 different ethnic origins; 29\% of the province’s population identify as non-White.\textsuperscript{10}

In Ontario, the COVID-19 immunization program involved a 3-phased distribution plan.\textsuperscript{11} Phase 1 (December 2020–March 2021) prioritized the limited vaccine supply for residents and staff in long-term care and retirement homes, healthcare workers, adults aged ≥ 80 years, and Indigenous adults. Ontario had initially followed the manufacturers’ recommended dosing schedules (ie, a 21-day interval for BNT162b2 and a 28-day interval for mRNA-1273), but in late January 2021 extended the interval to 35–42 days.\textsuperscript{12} In early March 2021, Ontario adopted the recommendation of National Advisory Committee on Immunization, the scientific body advising Health Canada on vaccinations, to delay administration of the second dose by up to 16 weeks.\textsuperscript{13} As vaccine supply and capacity to administer vaccines increased, the immunization program expanded to include additional priority populations over time. Phase 2 (April–June 2021) prioritized adults aged ≥ 55 years (in decreasing age group increments), high-risk congregate settings (eg, shelters, group homes), high-density “hot spot” regions (in large urban cities), certain essential caregivers, people unable to work from home, and individuals with certain health conditions. Specifically, provincial eligibility for immunocompromising health conditions or medications commenced May 3–6, before expanding to all adults aged ≥ 18 years on May 18. In June, the interval between doses was shortened due to increased supply. Eligibility for Phase 3 (July 2021 and beyond) involved the remaining individuals aged ≥ 12 years. To encourage vaccine uptake, the provincial government announced a COVID-19 vaccine pass-port system on September 1 that came into effect on September 22, 2021. With the exception of children ages < 12 years and those with accepted medical exemptions, all individuals must provide proof of identification and vaccination to access certain businesses and settings. Throughout Phase 3, additional levers and mandates were announced by provincial and federal levels of government and employers, targeting specific sectors/settings.

In the early distribution stage (Phase 1, up to March 2021), vaccines were distributed directly within high-risk settings (eg, hospitals, congregate care homes). In Phase 2 (April–June 2021), for the most part, early eligibility enabled residents to book appointments based on availability of vaccine supply/capacity. Therefore, simply being eligible for booking did not ensure all eligible individuals received vaccines during their time period of eligibility (as appointments could occur weeks after time of booking). Vaccine booking appointments were available at mass vaccination centers, selected pharmacies, and subsequently, primary care clinics. Walk-ins (without appointments) were also available at some of these sites if supply was available, and through community pop-up walk-in clinics and mobile units.

Study population. We studied all residents aged ≥ 16 years who were alive and actively enrolled in the Ontario Health Insurance Plan on December 14, 2020, when the immunization program began. Individuals meeting these criteria formed the general population group for this study. From within the general population group, individuals with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis (PsO), and inflammatory bowel disease (IBD) were identified using established disease-specific case definitions applied to health administrative data (Supplementary Table 1, available with the online version of this article). These case definitions comprised hospital and billing data that required multiple healthcare contacts for the condition of interest that were based on validation studies.\textsuperscript{14,15,16} These population-based cohorts have been extensively used for previous research purposes.\textsuperscript{17-19,20}

Vaccination status. Vaccination status was extracted between December 2020 and October 3, 2021. We obtained information regarding COVID-19 vaccination status, including vaccine product, date of administration, and dose number from COVaxON, a centralized COVID-19 vaccine registry in Ontario. COVaxON also captures COVID-19 vaccine doses for Ontario residents that are administered outside of province (regardless of the vaccine product) when residents provide proof to public health units. Dose administration date was used to determine the dose number as well as the dose interval (eg, number of days from first to second dose). Among individuals who received their first dose, we also ascertained the number of individuals who were at least 40 days overdue for their second dose to determine the potential vaccine dropouts, which is defined (according to the World Health Organization [WHO]) as the proportion of people who received at least 1 dose of a COVID-19 vaccine but did not receive a second dose yet.\textsuperscript{7}

Analysis. Descriptive statistics were used to characterize COVID-19 vaccines (all vaccine products and by product type) by dose, stratified by IMID diagnoses and the general population. The weekly cumulative percentage of individuals with 1 dose and 2 doses (determined separately) up until the end of study period (October 3, 2021) is expressed as the vaccinated proportion of each population. Age-specific estimates were determined separately. Analyses were conducted using SAS version 9.4 (SAS Institute). This study was approved by a privacy impact assessment at ICES (www.ices.on.ca), where all analyses were performed. The use of the data in this project was authorized under section 45 of Ontario’s Personal Health Information Protection Act, which does not require review by a research ethics board.

RESULTS

Our study population comprised 12,435,914 individuals in the general population, and 138,304 (1.1\%) individuals with RA, 28,509 (0.2\%) with AS, 17,646 (0.1\%) with PsA, 182,319 (1.5\%)

Downloaded on March 26, 2022 from www.jrheum.org
with PsO, and 108,792 (0.9%) with IBD. The age compositions of each population are presented in Supplementary Table 2 (available with the online version of this article). The RA cohort had the highest percentage (63.4%) of individuals aged ≥ 60 years (vs 29.6% for the general population).

By October 3, 2021, the cumulative percentage with 1 dose was 82.1% (95% CI 82.0–82.1) for the general population, 88.9% (95% CI 88.7–89.0) for RA, 87.4% (95% CI 87.0–87.7) for AS, 90.6% (95% CI 90.2–91.1) for PsA, 87.3% (95% CI 87.2–87.5%) for PsO, and 87.0% (95% CI 86.8–87.2) for IBD (Figure 1, Table 1). By the end of the study period, higher cumulative percentages with at least 1 dose were identified across all age-specific groups for IMIDs compared to the general population (Supplementary Figure 1, available with the online version of this article). Overall, older age groups had earlier uptake than younger age groups (corresponding with eligibility criteria). Within age groups, individuals with IMIDs in the youngest age group initially had earlier uptake than the general population of the same age (corresponding with eligibility criteria where younger individuals with IMIDs become eligible before the general population age group). However, as eligibility for health conditions followed older age eligibility, individuals with IMIDs in the older age groups did not have earlier uptake of first doses, although they ultimately ended up with a higher percentage vaccinated by the end of study period.

By October 3, 2021, there was a higher total cumulative percentage with 2 doses among individuals with IMIDs (83.8–88.2%) vs the general population (77.9%, 95% CI 77.9–77.9; Figure 2, Table 1). The difference between the IMID and general population groups was also evident when stratifying by age groups. Across age groups, individuals with IMIDs who were 60–79 years achieved the highest coverage with 2 doses, ranging from 89.2% (95% CI 89.0–89.4) for RA to 91.8% (95% CI 91.2–92.4) for PsA (Supplementary Figure 2, available with the online version of this article). By October 3, 2021, individuals aged 16–39 years were the lowest age group with 2 doses (cumulative percent of 70.6% [95% CI 70.5–70.6] in the general population vs 73.7–79.2% in patients with IMIDs).

Among those vaccinated, the majority of individuals (70.9–73.1%) received BNT162b2 vaccines (Table 1). The median interval between first and second doses ranged between 60–71 days for BNT162b2, 53–61 days for mRNA-1273, and 71–74 days for ChAdOx1 nCoV-19 (Supplementary Table 3, available with the online version of this article). Among those who were eligible for a second dose but failed to complete the 2-dose series by October 3, 2021, a slightly higher percentage of individuals was identified among those who received mRNA-1273 as their first dose (3–4% for mRNA-1273 vs 1–2% for BNT162b2).

**DISCUSSION**

COVID-19 vaccines have brought tremendous promise to help manage the pandemic. Ensuring high COVID-19 vaccine uptake among patients with IMIDs has been a priority for most COVID-19 immunization programs. However, the vaccination uptake among this group was previously unknown. We conducted a population-based study to analyze vaccine uptake among individuals with IMIDs and the general population in 1 province in Canada. Our study reveals higher COVID-19 vaccine uptake among individuals with IMIDs, surpassing the general population vaccination uptake of 78% with 2 doses as of October 2021.

![Figure 1. Cumulative percentage of each population with at least 1 dose by October 3, 2021.](www.jrheum.org)
COVID-19 vaccination among IMIDs

The WHO named vaccine hesitancy—the reluctance or refusal to vaccinate—as a threat to global health, and early studies on the acceptance of COVID-19 vaccines among individuals with IMIDs raised varied concerns that could contribute to additional vaccine hesitancy and thus lower uptake of COVID-19 vaccines in this patient population. While vaccine hesitancy varies considerably with nationality, and the implementation of COVID-19 immunization programs has also differed globally, a higher percentage of Ontario residents with IMIDs received COVID-19 vaccines in comparison to the general population. Therefore, for the most part, vaccine hesitancy did not appear to be increased among individuals with IMIDs. The earlier/faster uptake of COVID-19 vaccines among IMIDs is largely reflective of these individuals meeting earlier eligibility requirements through their advanced age, IMID diagnosis, preexisting comorbidities, or use of immunosuppressive therapies. Yet, despite Ontario having sufficient available supply and time to vaccinate the entire population, there is a subset of the IMID population that remains unvaccinated. Moreover, there is a difference between availability and accessibility of vaccines, and individuals with IMIDs are disproportionately affected with disabilities that can make accessibility of vaccination more challenging. Our study also identified a lower vaccine uptake in younger individuals, including those with IMIDs. Reasons are unknown, but this may be due to perceived lower risk, busier schedules, and/or clinical factors (eg, some patients

<table>
<thead>
<tr>
<th>Table 1. Overall summary of first and second vaccine doses administered to the study population as of October 3, 2021.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any Vaccine Type</td>
</tr>
<tr>
<td>Received at least 1 dose</td>
</tr>
<tr>
<td>Vaccine product of 1st dose</td>
</tr>
<tr>
<td>BNT162b2</td>
</tr>
<tr>
<td>mRNA-1273</td>
</tr>
<tr>
<td>ChAdOx1 nCoV-19</td>
</tr>
<tr>
<td>Received 2 doses</td>
</tr>
<tr>
<td>Interval between 2 doses, days</td>
</tr>
<tr>
<td>Individuals ≥ 40 days overdue for 2nd dose</td>
</tr>
</tbody>
</table>

Values are expressed as n (%) or median (IQR). * In total, the vaccine type was another product or unknown vaccine product in 3867 individuals. # Potential vaccine dropouts who failed to complete the 2-dose series. AS: ankylosing spondylitis; IBD: inflammatory bowel disease; PsA: psoriatic arthritis; PsO: psoriasis; RA: rheumatoid arthritis.

The WHO named vaccine hesitancy—the reluctance or refusal to vaccinate—as a threat to global health, and early studies on the acceptance of COVID-19 vaccines among individuals with IMIDs raised varied concerns that could contribute to additional vaccine hesitancy and thus lower uptake of COVID-19 vaccines in this patient population. While vaccine hesitancy varies considerably with nationality, and the implementation of COVID-19 immunization programs has also differed globally, a higher percentage of Ontario residents with IMIDs received COVID-19 vaccines in comparison to the general population. Therefore, for the most part, vaccine hesitancy did not appear to be increased among individuals with IMIDs. The earlier/faster uptake of COVID-19 vaccines among IMIDs is largely reflective of these individuals meeting earlier eligibility requirements through their advanced age, IMID diagnosis, preexisting comorbidities, or use of immunosuppressive therapies. Yet, despite Ontario having sufficient available supply and time to vaccinate the entire population, there is a subset of the IMID population that remains unvaccinated. Moreover, there is a difference between availability and accessibility of vaccines, and individuals with IMIDs are disproportionately affected with disabilities that can make accessibility of vaccination more challenging. Our study also identified a lower vaccine uptake in younger individuals, including those with IMIDs. Reasons are unknown, but this may be due to perceived lower risk, busier schedules, and/or clinical factors (eg, some patients

Figure 2. Cumulative percentage of each population with 2 doses by October 3, 2021.
might wait for a disease flare to resolve, some patients may be on prednisone and wait for a lower dose in order to have an effective vaccine response). While this study did not address which patient subgroups have lower vaccine uptake, a recent study by Vieira Rezende et al identified concurrent malignancy, certain comorbidities, and concurrent use of antirheumatic therapies as characteristics potentially associated with COVID-19 vaccine hesitancy among adults with IMIDs.7 Ongoing monitoring, identifying characteristics associated with lower vaccine uptake, and reducing potential inequities are warranted.

Strengths of our study include the population-based nature of our data, with near-complete capture of COVID-19 vaccines in a central repository. Additional public health measures such as a vaccine passport requirement has also likely encouraged reporting of vaccines administered out of province. Our findings may also be generalizable to other provinces and territories in Canada that have had a similar overall uptake in COVID-19 vaccines.

The data presented herein may differ from other sources for various reasons, including differing data extract times and methodologies for processing COVaxON data. Moreover, we acknowledge that populations are dynamic (eg, individuals move away) and we have studied only closed population-based cohorts who were alive and eligible for vaccination when the COVID-19 immunization program commenced. In Ontario, COVID-19 vaccines were freely available to anyone meeting eligibility requirements, regardless of whether they were Ontario residents with publicly funded healthcare coverage. Therefore, the totality of vaccines distributed in Ontario exceeds the results presented herein.

In conclusion, our study provides encouraging Canadian data regarding a high uptake of COVID-19 vaccines among individuals with IMIDs. However, the relatively lower uptake in younger individuals should be considered for novel targeted interventions. Ongoing surveillance of COVID-19 vaccines, including the safety and effectiveness of COVID-19 vaccines among patients with IMIDs, remains a priority to reduce the morbidity related to COVID-19/SARS-CoV-2 infection among this priority population.

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

REFERENCES


